AU2022337087A1 - Lou064 for treating multiple sclerosis - Google Patents

Lou064 for treating multiple sclerosis Download PDF

Info

Publication number
AU2022337087A1
AU2022337087A1 AU2022337087A AU2022337087A AU2022337087A1 AU 2022337087 A1 AU2022337087 A1 AU 2022337087A1 AU 2022337087 A AU2022337087 A AU 2022337087A AU 2022337087 A AU2022337087 A AU 2022337087A AU 2022337087 A1 AU2022337087 A1 AU 2022337087A1
Authority
AU
Australia
Prior art keywords
lou064
treatment
use according
multiple sclerosis
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022337087A
Other languages
English (en)
Inventor
Souvik Bhattacharya
Bruno BIETH
Bruno CENNI
Peter End
Gordon Graham
Michael Juhnke
Rajesh Singh Karan
Allison Donna MANN
Etienne PIGEOLET
Karin Rapp
Kim-Hien SIN
Huixin YU
Ying Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2022337087A1 publication Critical patent/AU2022337087A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2022337087A 2021-09-03 2022-09-01 Lou064 for treating multiple sclerosis Pending AU2022337087A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163240444P 2021-09-03 2021-09-03
US63/240,444 2021-09-03
US202163282363P 2021-11-23 2021-11-23
US63/282,363 2021-11-23
US202263304106P 2022-01-28 2022-01-28
US63/304,106 2022-01-28
US202263353866P 2022-06-21 2022-06-21
US63/353,866 2022-06-21
US202263369008P 2022-07-21 2022-07-21
US63/369,008 2022-07-21
PCT/IB2022/058205 WO2023031840A1 (en) 2021-09-03 2022-09-01 Lou064 for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
AU2022337087A1 true AU2022337087A1 (en) 2024-03-14

Family

ID=83438454

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022337087A Pending AU2022337087A1 (en) 2021-09-03 2022-09-01 Lou064 for treating multiple sclerosis

Country Status (10)

Country Link
US (1) US20240350489A1 (https=)
EP (1) EP4395779A1 (https=)
JP (2) JP7564347B2 (https=)
KR (1) KR20240055038A (https=)
AU (1) AU2022337087A1 (https=)
CA (1) CA3229887A1 (https=)
IL (1) IL310975A (https=)
MX (1) MX2024002581A (https=)
TW (1) TW202310841A (https=)
WO (1) WO2023031840A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
EP4522170A1 (en) * 2022-05-13 2025-03-19 Principia Biopharma Inc. Bruton tyrosine kinase inhibitors for use in the treatment of myelin oligodendrocyte glycoprotein antibody disease (mogad)
CN119744171A (zh) * 2022-06-24 2025-04-01 默克专利股份公司 自身免疫病和炎性疾病的治疗方案
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197080A1 (en) * 2010-08-02 2013-08-01 Sanofi Use of teriflunomide for treating multiple sclerosis
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
MX2020007312A (es) * 2018-01-08 2021-01-08 G1 Therapeutics Inc Regimenes de dosificacion superior de g1t38.
US12109193B2 (en) * 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
MX2021014161A (es) 2019-05-23 2022-01-04 Novartis Ag Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
HRP20251001T1 (hr) 2019-05-23 2025-10-24 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije
BR112021023054A2 (pt) 2019-05-23 2022-03-29 Novartis Ag Formas cristalinas de um inibidor de btk
WO2022081512A1 (en) * 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
TWI905371B (zh) * 2021-01-26 2025-11-21 瑞士商諾華公司 藥物組成物
EP4301365A1 (en) * 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor

Also Published As

Publication number Publication date
MX2024002581A (es) 2024-03-20
KR20240055038A (ko) 2024-04-26
TW202310841A (zh) 2023-03-16
EP4395779A1 (en) 2024-07-10
JP2023542878A (ja) 2023-10-12
JP2024178420A (ja) 2024-12-24
US20240350489A1 (en) 2024-10-24
IL310975A (en) 2024-04-01
JP7564347B2 (ja) 2024-10-08
WO2023031840A1 (en) 2023-03-09
CA3229887A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
US20240350489A1 (en) Lou064 for treating multiple sclerosis
JP7365381B2 (ja) 血小板由来成長因子受容体アルファの遺伝的異常に関連する癌の治療のための、１－［４－ブロモ－５－［１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル］－２－フルオロフェニル］－３－フェニルウレアおよびアナログの使用
TW202140002A (zh) 用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑
JP2025165957A (ja) ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法
D’Amico et al. Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal
CN115209899A (zh) 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法
KR20240004451A (ko) Ilt7 결합 단백질을 이용한 자가면역 장애의 치료 방법
EP4707302A2 (en) Ofatumumab for treating ms while maintaining serum igg
US20090105281A1 (en) Methods of treating inflammation
US20250032488A1 (en) Methods of treatment using lou064
EA051716B1 (ru) Lou064 для лечения рассеянного склероза
CN118019540A (zh) 用于治疗多发性硬化的lou064
WO2021072095A1 (en) Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
Szollosi et al. Mechanisms of Autoimmunity and Pharmacologic Treatments
US20240254218A1 (en) Compositions and methods for treating neurodegenerative diseases by inhibiting fsh
Egan-Auderset 8th Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) Meeting (MSVirtual2020). Virtual-September 11-13, 2020
WO2024126431A1 (en) Anti-ilt7 binding agents for the treatment and prevention of myositis
WO2024155810A1 (en) Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy
CN117440827A (zh) 使用抗cd19抗体治疗重症肌无力
IL324517A (en) Methods for treating dermatomyositis with brepoxitinib
JP2022546686A (ja) 形質細胞に対する抑制剤または細胞傷害剤を使用する慢性疲労症候群の処置のための方法
CN117561076A (zh) 使用ilt7结合蛋白治疗自体免疫病症的方法
HK40051003A (en) Treatment of rms by switching therapy
HK40051003B (en) Treatment of rms by switching therapy
Ramtahal A pilot multi-centre randomised controlled trial of sequential mitoxantrone and glatiramer acetate vs. interferon beta-1a in early active relapsing remitting multiple sclerosis